Navigation Links
AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical,Pipeline to Be Featured at AACR

nomic Analysis of Human Cancer - Room 304 A-C

-- Wednesday, April 18, 2007 at 10:25 a.m. to 10:40 a.m. "A novel chimeric approach to modeling cancer in mice reveals that EGFR dependency in lung tumors is mediated through non canonical RTK-MAPK signaling" - Mini-symposium: Mouse Models of Cancer - Room 406 A-B

-- Wednesday, April 18, 2007 at 10:40 a.m. to 10:55 a.m. "Genetically engineered human breast cancer in mouse (HIM): A novel cancer model system that progresses in vivo and exhibits phenotypic variations" - Mini-symposium: Mouse Models of Cancer - Room 406 A-B

The schedule for poster presentations at the AACR Annual Meeting is listed below:

-- Monday, April 16, 2007 at 8:00 a.m. to 12:00 p.m. "Genetically engineered murine tumor models for drug response prediction: Population based pathway profiles predict response to repamycin in a HER2 driven breast model" - Poster Session: Mouse Models in Cancer - Section 23, Board 28

-- Monday, April 16, 2007 at 1:00 p.m. to 5:00 p.m. "Directed complementation of inducible tumor models: An approach to generate broad panels of tumors with defined genetic contexts" - Poster Session: Mouse Models of Cancer - Section 22, Board 29

-- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. "AV-412, a potent EGFR/HER2 TK inhibitor causes tumor regression in novel genetically engineered EGFRL858R and EGFRL858R and T790M lung tumor models" - Poster Session: EGFR Inhibition - Section 28, Board 6

-- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. "A novel beta-Catenin dependent p53DN mouse model of colon cancer displays stage dependent expression of EGFR" - Poster Session: Mouse Models of Cancer - Section 20, Board 9

-- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. "A chimeric mouse model of ovarian cancer driven by inducible expression of PI3K catalytic subunit (p110alpha)" - Poster Session: Mouse Models of Cancer - Section 21, Board 4

-- Tuesday, April 17, 2007 at 8:0
'"/>




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:10/1/2014)... 2014  Varian Medical Systems (NYSE: VAR ... the fourth quarter of fiscal year 2014 following the ... The news release will be followed by a teleconference ... The news release and a link to the conference ... at: www.varian.com/investor .  To access the teleconference call ...
(Date:10/1/2014)... Oct. 1, 2014 Quantum Materials Corp ... production of photoactive quantum dots for use in ... offering numerous advantages for solar power generation, the ... of quantum dots with which to develop thin ... from commercial utilization and acceptance. The company is ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
Breaking Medicine Technology:Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... Medical, Inc. announces the addition of the BioTech Medical ... to its ever expanding line of innovative ... goes by that our office doesn,t receive a call for ... BioTech Medical, Inc.  "We listened to our customers, and now, ...
... Md., July 18, 2011 MedImmune announced today ... Live, Intranasal) to influenza vaccine distributors who service ... MedImmune expects to provide approximately 15 ... spray flu vaccine for the 2011-2012 influenza season ...
Cached Medicine Technology:FluMist® (Influenza Vaccine Live, Intranasal) Begins Shipping for 2011-2012 Influenza Season 2FluMist® (Influenza Vaccine Live, Intranasal) Begins Shipping for 2011-2012 Influenza Season 3
(Date:10/2/2014)... Philadelphia, PA (PRWEB) October 02, 2014 ... winners of the 2014 BIG Awards for Business ... companies and organizations with a proprietary judging process ... from around the globe. , “The winners this ... said Russ Fordyce, Managing Director of the Business ...
(Date:10/2/2014)... Salamon HealthDay Reporter ... with a neurotic personality style and prolonged stress may ... research suggests. Tracking 800 women over nearly four ... anxious, jealous and moody -- which they defined as ... risk of developing Alzheimer,s compared to women scoring lowest ...
(Date:10/2/2014)... Steven Reinberg HealthDay Reporter ... to a major highway may raise your risk for high ... 5,000 postmenopausal women, those who lived within 109 yards of ... developing high blood pressure than women living at least half ... this study highlight the importance of our physical environment on ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... Columbia now have a total of 500 confirmed cases of ... children since the summer, U.S. health officials reported Wednesday. ... recent weeks, but it,s not clear what role -- if ... Health officials are also trying to determine if the ...
(Date:10/1/2014)... more than 80 per cent of bowel cancers could ... that medicines called ,JAK inhibitors, halted tumour growth in ... in more than 80 per cent of bowel cancers. ... clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood ... second-most common cancer in Australia with nearly 17,000 people ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2
... and British scientists have now found that it is helpful in ... warfare. , ... Manhasset, NY (Vocus) May 6, 2009 ... found that it is helpful in delaying the effects of ricin, ...
... May 6 Parishioners at Guardian Angels Catholic Church in ... shelf -- they actually grow it themselves. The project is ... by the Institute for Agriculture and Trade Policy (IATP) and ... Cross) that demonstrate a growing nationwide movement within the faith ...
... 6 Symmetry Medical Inc. (NYSE: SMA ), ... device industry and other medical markets, announced today that Brian ... Hite, Senior Vice President and Chief Financial Officer, are scheduled ... 2009 Healthcare Conference at the Palace Hotel in New York ...
... Mich., May 6 Perrigo Company (Nasdaq: ... Directors declared a quarterly dividend of $0.055 per share, ... on May 29, 2009. Perrigo Company is a leading ... (OTC) and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ...
... PA, 6 May 2009 Obstructive sleep apnea (OSA) ... in heart failure (HF) patients managed with beta-blockers and ... Journal of Cardiac Failure ( http://www.elsevier.com/locate/cardfail ), ... of Sleep Apnea in Patients with Heart Failure and ...
... lack of guidance and training provided for nurses involved in ... , Writing in the May issue of the Journal ... highlighted the need for an audit of current UK services ... , But they point out that the basic issues they ...
Cached Medicine News:Health News:Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine 2Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 2Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 3Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 4Health News:Symmetry Medical to Present at Bank of America and Merrill Lynch 2009 Healthcare Conference 2Health News:Sleep apnea may not be closely linked to heart failure severity 2Health News:Nurses are assessing mothers with mental health issues despite lack of guidance and formal training 2Health News:Nurses are assessing mothers with mental health issues despite lack of guidance and formal training 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: